HC Wainwright Has Bearish Forecast for BRNS FY2025 Earnings

Barinthus Biotherapeutics plc (NASDAQ:BRNS) – Equities research analysts at HC Wainwright decreased their FY2025 EPS estimates for Barinthus Biotherapeutics in a research note issued on Monday, May 12th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($1.35) per share for the year, down from their prior forecast of ($1.16). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Barinthus Biotherapeutics’ current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Barinthus Biotherapeutics’ FY2026 earnings at ($1.19) EPS.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.15).

Separately, Alliance Global Partners reissued a “buy” rating on shares of Barinthus Biotherapeutics in a research report on Monday, March 24th.

Barinthus Biotherapeutics Stock Down 2.2%

NASDAQ:BRNS opened at $0.91 on Wednesday. Barinthus Biotherapeutics has a 52 week low of $0.64 and a 52 week high of $2.44. The company has a market cap of $36.70 million, a price-to-earnings ratio of -0.61 and a beta of -0.80. The company has a fifty day simple moving average of $0.88 and a two-hundred day simple moving average of $1.01.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. HighTower Advisors LLC acquired a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 37,450 shares of the company’s stock, valued at approximately $36,000. HighTower Advisors LLC owned 0.09% of Barinthus Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.